revlimidhcp.com | Multiple Myeloma Treatment Option

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Sitemap:

Meta Tags

Title	Multiple Myeloma Treatment Option \| REVLIMID®
Description	The only FDA-approved maintenance Learn more about REVLIMID®, a treatment option for multiple myeloma. See safety info and BOXED WARNINGS on fetal and hem tox & blood
Keywords	N/A

Server Information

WebSite	revlimidhcp.com
Host IP	45.60.170.161
Location	United States

Related Websites

                        Site
                        Rank
                    

More to Explore

revlimidhcp.com Valuation

US$17,927,890

Last updated: 2023-04-28 23:13:03

revlimidhcp.com has Semrush global rank of 590,382. revlimidhcp.com has an estimated worth of US$ 17,927,890, based on its estimated Ads revenue. revlimidhcp.com receives approximately 2,068,603 unique visitors each day. Its web server is located in United States, with IP address 45.60.170.161. According to SiteAdvisor, revlimidhcp.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$17,927,890
Daily Ads Revenue	US$16,549
Monthly Ads Revenue	US$496,465
Yearly Ads Revenue	US$5,957,576
Daily Unique Visitors	137,907
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
revlimidhcp.com.	A	300	IP: 45.60.170.161
revlimidhcp.com.	A	300	IP: 45.60.150.161
revlimidhcp.com.	NS	86400	NS Record: ns-657.awsdns-18.net.
revlimidhcp.com.	NS	86400	NS Record: ns-1371.awsdns-43.org.
revlimidhcp.com.	NS	86400	NS Record: ns-1931.awsdns-49.co.uk.
revlimidhcp.com.	NS	86400	NS Record: ns-456.awsdns-57.com.
revlimidhcp.com.	TXT	300	TXT Record: facebook-domain-verification=072hnzf5cilttuuexcuqcdywbzo604
revlimidhcp.com.	TXT	300	TXT Record: facebook-domain-verification=7qzyqkvij8aj5bc2zyo8xus58pvz6m
revlimidhcp.com.	TXT	300	TXT Record: google-site-verification=ig_obL78b4uJUeXnV9nAjZZbQkA53MS-35xrs6OC0e0
revlimidhcp.com.	TXT	300	TXT Record: ec94e47e95e44f73bfd8ed8fe33d2d7d

HtmlToTextCheckTime:2023-04-28 23:13:03

Indication Prescribing Information Med Guide BMS Resources BMS Access Support ® Lenalidomide REMS Visit Patient & Caregiver Website See other indications for REVLIMID: Multiple Myeloma Myelodysplastic Syndromes Mantle Cell Lymphoma Follicular Lymphoma & Marginal Zone Lymphoma This website is intended for U.S. Healthcare Professionals. About REVLIMID About REVLIMID Disease Overview Mechanism of Action IMiD ® FOUNDATION Combinations with REVLIMID Combinations with REVLIMID Rd Efficacy Safety Dosing AE Dose Modifications DRd Efficacy Safety In this section, Rd and DRd are combinations with REVLIMID in NSCT NDMM. Information about DRd does not appear in the REVLIMID full Prescribing Information. Please see the daratumumab full Prescribing Information and Important Safety Information at www.darzalexhcp.com/iv . Maintenance Therapy Maintenance Therapy Efficacy Safety Dosing AE Dose Modifications Explore dosing for all levels of renal impairment . Continuous Treatment Continuous Treatment Rd

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Thu, 21 Oct 2021 21:45:24 GMT
Content-Type: text/html; charset=iso-8859-1
Connection: keep-alive
Set-Cookie: AWSALBTG=sPsLrBamXOlXQZlTLtj8DZHSKbiIPXjM/s+lF+EJjNPh/fZL8P3l0GmebDWmo+IMDWSzZUl0zmEQ8rrWE6XSPsvToWD1B1wjh7yYPg18Ll1WyqoUK4hC03pWGTi1ventG8yFlDeCvsjJfRlRlkqLBzeF/iPKRPdrvPFBFVZSZ3QPNPCTuSI=; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/
Set-Cookie: AWSALBTGCORS=sPsLrBamXOlXQZlTLtj8DZHSKbiIPXjM/s+lF+EJjNPh/fZL8P3l0GmebDWmo+IMDWSzZUl0zmEQ8rrWE6XSPsvToWD1B1wjh7yYPg18Ll1WyqoUK4hC03pWGTi1ventG8yFlDeCvsjJfRlRlkqLBzeF/iPKRPdrvPFBFVZSZ3QPNPCTuSI=; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/; SameSite=None
Server: Apache
Location: https://revlimidhcp.com/
Set-Cookie: AWSALBAPP-0=_remove_; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/
Set-Cookie: AWSALBAPP-1=_remove_; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/
Set-Cookie: AWSALBAPP-2=_remove_; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/
Set-Cookie: AWSALBAPP-3=_remove_; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/
Set-Cookie: visid_incap_2613599=ITLvv3tqSm++rKmeez0FQ3PfcWEAAAAAQUIPAAAAAADlh71hagSHwJqL2TsW8AeC; expires=Fri, 21 Oct 2022 07:50:47 GMT; HttpOnly; path=/; Domain=.revlimidhcp.com
Set-Cookie: incap_ses_512_2613599=hA8+Tce3hyu4bs2eyf0aB3PfcWEAAAAA4aJkMOZgCZ+B3N6Fcr5efQ==; path=/; Domain=.revlimidhcp.com
Set-Cookie: ___utmvmBauLNzRZ=xwRcwoTOpVt; path=/; Max-Age=900
Set-Cookie: ___utmvaBauLNzRZ=rgbFxBL; path=/; Max-Age=900
Set-Cookie: ___utmvbBauLNzRZ=lZy
    XWZOnall: mta; path=/; Max-Age=900
X-CDN: Imperva
X-Iinfo: 1008-23263833-23263857 NNNN CT(21 -1 0) RT(1634852723751 1) q(0 2 2 0) r(2 2) U6

HTTP/2 200 
date: Thu, 21 Oct 2021 21:45:25 GMT
content-type: text/html; charset=UTF-8
set-cookie: AWSALBTG=m3SouUhS0/rkybV5xe8SUV4s2mgpxd/c9zc1lXZfRK/CVvMXsmrUI+8puMdHmGuHNgYVlphYhO3aR7fdmQfSNRzoAkLYgXPSv7zuC/p54E3zzFdpjvN6Mwp05rjajdLsVfV8ss46PFrjH6Wdej/ZmVsiOO465RbVN2JBnxMMC3xZ6jJrzX0=; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/
set-cookie: AWSALBTGCORS=m3SouUhS0/rkybV5xe8SUV4s2mgpxd/c9zc1lXZfRK/CVvMXsmrUI+8puMdHmGuHNgYVlphYhO3aR7fdmQfSNRzoAkLYgXPSv7zuC/p54E3zzFdpjvN6Mwp05rjajdLsVfV8ss46PFrjH6Wdej/ZmVsiOO465RbVN2JBnxMMC3xZ6jJrzX0=; Expires=Thu, 28 Oct 2021 21:45:24 GMT; Path=/; SameSite=None; Secure
server: Apache
link: ; rel="https://api.w.org/"
link: ; rel="alternate"; type="application/json"
link: ; rel=shortlink
x-xss-protection: 1; mode=block
set-cookie: AWSALBAPP-0=_remove_; Expires=Thu, 28 Oct 2021 21:45:25 GMT; Path=/
set-cookie: AWSALBAPP-1=_remove_; Expires=Thu, 28 Oct 2021 21:45:25 GMT; Path=/
set-cookie: AWSALBAPP-2=_remove_; Expires=Thu, 28 Oct 2021 21:45:25 GMT; Path=/
set-cookie: AWSALBAPP-3=_remove_; Expires=Thu, 28 Oct 2021 21:45:25 GMT; Path=/
set-cookie: visid_incap_2613599=8x4p7/M5RwajJD3gE7OHwnTfcWEAAAAAQUIPAAAAAACQy9AMtBFvSbGKq5Dfwgqv; expires=Fri, 21 Oct 2022 07:26:14 GMT; HttpOnly; path=/; Domain=.revlimidhcp.com
set-cookie: incap_ses_303_2613599=+WeNVhFdGV5HL4H/+Xg0BHXfcWEAAAAA7NJL7gsMrtUNfH5shWXkFg==; path=/; Domain=.revlimidhcp.com
x-cdn: Imperva
x-iinfo: 11-54549629-54549635 NNNN CT(21 45 0) RT(1634852724361 0) q(0 0 1 29) r(8 8) U6

revlimidhcp.com Whois Information

Domain Name: REVLIMIDHCP.COM
Registry Domain ID: 2414144099_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corporatedomains.com
Registrar URL: http://cscdbs.com
Updated Date: 2021-07-14T05:08:21Z
Creation Date: 2019-07-18T16:35:11Z
Registry Expiry Date: 2022-07-18T16:35:11Z
Registrar: CSC Corporate Domains, Inc.
Registrar IANA ID: 299
Registrar Abuse Contact Email: domainabuse@cscglobal.com
Registrar Abuse Contact Phone: 8887802723
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS-1371.AWSDNS-43.ORG
Name Server: NS-1931.AWSDNS-49.CO.UK
Name Server: NS-456.AWSDNS-57.COM
Name Server: NS-657.AWSDNS-18.NET
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-10T16:42:08Z <<<

revlimidhcp.com valuation and analysis